.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,293,794

« Back to Dashboard

Claims for Patent: 8,293,794

Title:Methods and compositions for the treatment of CNS-related conditions
Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:12/753,769
Patent Claims: 1. A pharmaceutical composition comprising: (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) in a defined time period of 0 to 6 hours after administration, as measured in a single-dose human PK study, that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine during said defined time period; and (b) a therapeutically effective amount of an ACheI or a pharmaceutically acceptable salt thereof selected from the group consisting of donepezil, rivastigmine and galantamine.

2. A pharmaceutical composition of claim 1, wherein the ACheI is donepezil.

3. The composition of claim 1 wherein the concentration profile is further characterized by a maximum memantine plasma concentration to mean memantine plasma concentration ratio (Cmax/Cmean) of about 2.5 to 2 at 1 hour to at least 6 hours after administration.

4. The composition of claim 1, wherein at least 98% of the memantine is in an extended release form.

5. The composition of claim 1, wherein the composition is a capsule and wherein the memantine, or pharmaceutically acceptable salt thereof, is formulated as pellets.

6. The composition of claim 5, wherein the pellets comprise an extended release coating.

7. The composition of claim 6, wherein the extended release coating comprises an insoluble matrix polymer and a water soluble material.

8. The composition of claim 7, wherein the insoluble matrix polymer comprises ethyl cellulose and the water soluble material comprises polyvinylpyrrolidone.

9. The composition of claim 1 comprising 12.5-40 mg memantine or a pharmaceutically acceptable salt thereof.

10. The composition of claim 1 comprising 25-40 mg memantine or a pharmaceutically acceptable salt thereof.

11. The composition of claim 1, wherein the extended release memantine dosage form further comprises, ethyl cellulose, polyethylene glycol, hydroxypropylmethyl cellulose and polyvinylpyrrolidone.

12. The composition of claim 1, wherein the ACheI is donepezil or a pharmaceutically acceptable salt thereof.

13. The composition of claim 12 wherein the donepezil or pharmaceutically acceptable salt thereof is in an immediate release form.

14. The composition of claim 1, wherein said extended release memantine or pharmaceutically acceptable salt thereof has an in vitro dissolution of less than 30% in one hour, less than 40% in two hours and greater than 40% in six hours as measured using a USP type 2 (paddle) dissolution system at 50 rpm, at a temperature of 37.+-.0.5.degree. C. with water as a dissolution medium.

15. A pharmaceutical composition comprising: (a) 5 to 40 mg memantine or a pharmaceutically acceptable salt thereof provided in an extended release dosage form, wherein said extended release memantine or pharmaceutically acceptable salt thereof provides a change in plasma concentration as a function of time (dC/dT) that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine during said defined time period, wherein the dC/dT is measured in a single dose human PK study between the time period of 0 to Tmax of the immediate release form of memantine; and (b) a therapeutically effective amount of an ACheI or a pharmaceutically acceptable salt thereof selected from the group consisting of donepezil, rivastigrnine and galantamine.

16. A pharmaceutical composition of claim 15, wherein the ACheI is donepezil.

17. The composition of claim 15, wherein the concentration profile is further characterized by a maximum memantine plasma concentration to mean memantine plasma concentration ratio (Cmax/Cmean) of about 2.5 to 2 at 1 hour to at least 6 hours after administration.

18. The composition of claim 15, wherein at least 98% of the memantine is in an extended release form.

19. The composition of claim 15, wherein the composition is a capsule and wherein the memantine, or pharmaceutically acceptable salt thereof, is formulated as pellets.

20. The composition of claim 19, wherein the pellets comprise an extended release coating.

21. The composition of claim 20, wherein the extended release coating comprises an insoluble matrix polymer and a water soluble material.

22. The composition of claim 21, wherein the insoluble matrix polymer comprises ethyl cellulose and the water soluble material comprises polyvinylpyrrolidone.

23. The composition of claim 15, comprising 12.5-40 mg memantine or a pharmaceutically acceptable salt thereof.

24. The composition of claim 15, comprising 25-40 mg memantine or a pharmaceutically acceptable salt thereof.

25. The composition of claim 15, wherein the extended release memantine dosage form further comprises, ethyl cellulose, polyethylene glycol, hydroxypropylmethyl cellulose and polyvinylpyrrolidone.

26. The composition of claim 15, wherein the ACheI is donepezil or a pharmaceutically acceptable salt thereof.

27. The composition of claim 26, wherein the donepezil or pharmaceutically acceptable salt thereof is in an immediate release form.

28. The composition of claim 15, wherein said extended release memantine or pharmaceutically acceptable salt thereof has an in vitro dissolution of less than 30% in one hour, less than 40% in two hours and greater than 40% in six hours as measured using a USP type 2 (paddle) dissolution system at 50 rpm, at a temperature of 37.+-.0.5.degree. C. with water as a dissolution medium.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc